.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR06_EmtricitabineTenofovirDi.EmtricitabineTenofovirDi .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR06_EmtricitabineTenofovirDi.EmtricitabineTenofovirDi| name: | EmtricitabineTenofovirDisoproxilAndEfavirenz | |
| ATC code: | J05AR06 | route: | oral |
| compartments: | 1 | |
| dosage: | 1100 | mg |
| volume of distribution: | 75 | L |
| clearance: | 9.8 | L/h |
| other parameters in model implementation | ||
A fixed-dose combination of three antiretroviral medications: emtricitabine (a nucleoside reverse transcriptase inhibitor), tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor), and efavirenz (a non-nucleoside reverse transcriptase inhibitor). Used for the treatment of HIV-1 infection in adults and children and is currently approved for use.
Pharmacokinetics in healthy HIV-negative adults receiving a single oral fixed-dose combination tablet (emtricitabine 200 mg, tenofovir disoproxil fumarate 300 mg, efavirenz 600 mg) under fasting conditions.